Bloomberg News
@Bloomberg-News·2.8M subscribers·40.1K videos
A Million Americans Are Taking Ozempic Copycats
Posted
August 3, 2025
Views
3,454
Likes
68
Comments
3
Engagement
2.06%
August 3, 2025
3,454
68
3
2.06%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
1:42Now PlayingNovo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years after Wegovy’s US launch, the Danish drugmaker’s growth is slowing. About one million patients in the US are taking cheaper copycat options. To reverse this decline, Novo named a new chief executive this week to win them back – and prove the company can still compete with US rival Eli Lilly & Co.
----------
Like this video? Subscribe
Bloomberg News is the first word in business news. Visit bloomberg.com for the latest on global business, markets and more.
Get unlimited access to Bloomberg.com for $1.99/month for the first 3 months
Bloomberg on YouTube:
Connect with us on social:
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
